Stifel bumps Nvidia stock target, sees attractive valuation
Relay Therapeutics (NASDAQ:RLAY) Chief Corporate Development Officer, Peter Rahmer, sold a total of 17,083 shares of common stock on July 28 and 29, 2025. The sales were executed in two separate transactions, with prices ranging from $3.68 to $3.74, and the total value of shares sold was $62,946. The stock, currently trading at $3.63, has shown significant volatility this year with a 52-week range of $1.77 to $10.72. According to InvestingPro analysis, the company appears undervalued at current levels.
On July 28, Rahmer sold 1,359 shares at a price of $3.74 per share. Following this transaction, Rahmer directly owned 393,722 shares, including 199,209 shares underlying Restricted Stock Units (RSUs).
The second sale occurred on July 29, with Rahmer selling 15,724 shares at $3.68 per share. After this transaction, Rahmer directly owned 377,998 shares, which includes 156,816 shares underlying RSUs.
According to the footnotes in the SEC filing, the sales were to cover income tax withholding obligations upon the vesting of RSUs, and Rahmer had no discretion over these sales, which were transacted according to Relay Therapeutics’ policies. With the company’s next earnings report scheduled for August 12, 2025, investors can access detailed financial analysis and Fair Value estimates through InvestingPro’s exclusive research reports.
In other recent news, Relay Therapeutics has reported consistent and promising results from its Phase 2 ReDiscover trial concerning its investigational drug RLY-2608. The updated data, presented at the American Society of Clinical Oncology (ASCO) conference, reveal a median progression-free survival (PFS) of 10.3 months overall, with a notable 11.0 months in second-line patients. These findings are particularly relevant for patients with PI3Kα-mutated, HR+, HER2- locally advanced or metastatic breast cancer, who received RLY-2608 in combination with fulvestrant. Additionally, the trial showed an increase in median progression-free survival by seven months, with an overall improvement of 1.1 months compared to earlier data.
Following this data presentation, Citizens JMP analysts reaffirmed their Market Outperform rating for Relay Therapeutics, maintaining the price target at $12.00. This decision underscores the analysts’ confidence in the potential of RLY-2608 for treating PIK3CA-mutated metastatic breast cancer. These developments highlight Relay Therapeutics’ ongoing progress in the clinical-stage precision medicine field.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.